GlassScriptPhysician profile
Parminder Minhas
NPI 1932581592
$5,565.33
in general payments reported to CMS, 2019-2025
31 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $123 · 2022: $1,339 · 2023: $2,564 · 2024: $969 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,883.00 |
| Travel and Lodging | $877.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,184.62 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $955.37 | 2022-2024 | Da Vinci Surgical System |
| Insmed, INC. | $595.39 | 2022-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $524.38 | 2019-2024 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $500.07 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $300.97 | 2022-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Novartis Pharmaceuticals Corporation | $182.14 | 2022-2024 | |
| Gilead Sciences, INC. | $132.71 | 2022-2023 | |
| Actelion Pharmaceuticals US, INC. | $126.80 | 2019-2023 | Opsumit |
| Baxter Healthcare | $120.15 | 2023-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $108.73 | 2023-2025 | |
| Amgen INC. | $82.79 | 2022-2024 | Tezspire |
| Genentech USA, INC. | $63.51 | 2022-2023 | Xolair |
| Jazz Pharmaceuticals INC. | $59.78 | 2019-2020 | |
| La Jolla Pharmaceutical Company | $57.31 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $55.36 | 2019-2024 | Tyvaso |
| Grifols USA, LLC | $51.71 | 2023 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $49.33 | 2019-2023 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $49.09 | 2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $48.25 | 2022-2024 | Glassia |
| Fisher & Paykel Healthcare INC | $42.71 | 2022-2025 | Fisher & Paykel Healthcare |
| Vifor Pharma, INC. | $40.97 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.21 | 2019-2020 | |
| Philips North America LLC | $30.90 | 2023-2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $30.89 | 2023 | |
| Pfizer INC. | $30.85 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $25.82 | 2020 | |
| Portola Pharmaceuticals, LLC | $25.01 | 2019 | |
| Janssen Biotech, INC. | $20.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.03 | 2019 | |
| Inspire Medical Systems, INC. | $14.27 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parminder Minhas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.